View ValuationKORU Medical Systems 将来の成長Future 基準チェック /46KORU Medical Systemsは、93.4%と14.6%でそれぞれ年率93.4%で利益と収益が成長すると予測される一方、EPSはgrowで93.3%年率。主要情報93.4%収益成長率93.25%EPS成長率Medical Equipment 収益成長16.7%収益成長率14.6%将来の株主資本利益率n/aアナリストカバレッジLow最終更新日07 May 2026今後の成長に関する最新情報Price Target Changed • Mar 13Price target increased by 8.8% to US$6.80Up from US$6.25, the current price target is an average from 5 analysts. New target price is 59% above last closing price of US$4.28. Stock is up 55% over the past year. The company is forecast to post a net loss per share of US$0.03 next year compared to a net loss per share of US$0.081 last year.Price Target Changed • Dec 22Price target increased by 11% to US$6.25Up from US$5.65, the current price target is an average from 5 analysts. New target price is approximately in line with last closing price of US$6.07. Stock is up 54% over the past year. The company is forecast to post a net loss per share of US$0.07 next year compared to a net loss per share of US$0.13 last year.Major Estimate Revision • Nov 19Consensus estimates of losses per share improve by 12%The consensus outlook for earnings per share (EPS) in fiscal year 2025 has improved. 2025 revenue forecast increased from US$39.9m to US$40.7m. EPS estimate increased from -US$0.08 per share to -US$0.07 per share. Medical Equipment industry in the US expected to see average net income growth of 15% next year. Consensus price target broadly unchanged at US$5.56. Share price rose 19% to US$4.45 over the past week.お知らせ • Nov 13KORU Medical Systems, Inc. Revises Earnings Guidance for the Year 2025KORU Medical Systems, Inc. revised earnings guidance for the year 2025. The company is raising full year 2025 net revenues guidance to $40.5 million - $41.0 million, representing year-over-year growth of 20% - 22%, from prior range of $39.5 million - $40.5 million.お知らせ • Aug 07KORU Medical Systems, Inc. Raises Earnings Guidance for the Year 2025KORU Medical Systems, Inc. raising earnings guidance for the year 2025. For the year, the company raising full year 2025 revenue guidance to $39.5 - $40.5 million, representing growth of 18% - 20%, from prior range of $38.5 - $39.5 million.お知らせ • May 08Koru Medical Systems, Inc. Raises Earnings Guidance for Full Year 2025KORU Medical Systems, Inc. raised earnings guidance for full year 2025. For the period the company raising revenue guidance to $38.5 million to $39.5 million from prior range of $38.0 million to $39.0 million.すべての更新を表示Recent updatesお知らせ • Jul 16KORU Medical Systems, Inc. to Report Q2, 2026 Results on Aug 05, 2026KORU Medical Systems, Inc. announced that they will report Q2, 2026 results on Aug 05, 2026ナラティブ更新 • Jun 26KRMD: Increasing Home Infusion Adoption Will Support Higher Future Earnings PowerAnalysts have raised their fair value estimate for KORU Medical Systems to $5.00 from $4.00, reflecting updated assumptions regarding revenue growth, profit margins, and a lower future P/E multiple in their valuation work. What's in the News KORU Medical Systems presented new research at the Oncology Nursing Society Congress, highlighting its FreedomEDGE infusion system in subcutaneous monoclonal antibody administration across four U.S. community infusion centers, source: company key developments.お知らせ • May 20Koru Medical Systems Presents Real World Data on the Benefits of the Freedomedge Syringe Infusion SystemKORU Medical Systems, Inc. presented its latest research at the Oncology Nursing Society Congress, May 13-17. The poster at ONS was titled, “Reducing Ergonomic Strain During Subcutaneous Monoclonal Antibody Administration.” The ONS abstract evaluated nursing workflow, nurse experience, and patient-reported outcomes after implementing KORU Medical's FreedomEDGE infusion system for subcutaneous drug administration across four community infusion centers in the United States. The findings demonstrated: Efficiency- 100% of doses successfully administered with infusion times aligned with clinical guidelines. Reduced Strain- Nurses experienced significantly less strain after implementing pump assisted or tubing-needle set assisted drug administration. High Satisfaction- Both nurses (4.85/5) and patients (4.92/5) reported high satisfaction levels. Workflow advantages- Nurses reported ability to multitask during 80% of pump infusions. KORU Medical’s FREEDOM Syringe Infusion System enables, simplifies, and enhances the delivery of large-volume subcutaneous drugs. Supporting drug products with various requirements for viscosity, flow rate, and delivered drug volume from 5mL-50mL+, the Freedom System is market proven with: 15+ years of patient self-administration in the home. 59,000+ patients and over 3M infusions annually. 97% adherence rate and 9 on-label subcutaneous drugs. Approval in 30+ countries.Reported Earnings • May 07First quarter 2026 earnings released: US$0.017 loss per share (vs US$0.025 loss in 1Q 2025)First quarter 2026 results: US$0.017 loss per share (improved from US$0.025 loss in 1Q 2025). Revenue: US$11.8m (up 22% from 1Q 2025). Net loss: US$807.1k (loss narrowed 31% from 1Q 2025). Revenue is forecast to grow 15% p.a. on average during the next 3 years, compared to a 8.0% growth forecast for the Medical Equipment industry in the US. Over the last 3 years on average, earnings per share has increased by 38% per year but the company’s share price has only increased by 4% per year, which means it is significantly lagging earnings growth.お知らせ • Apr 16KORU Medical Systems, Inc. to Report Q1, 2026 Results on May 06, 2026KORU Medical Systems, Inc. announced that they will report Q1, 2026 results on May 06, 2026お知らせ • Apr 10KORU Medical Systems, Inc., Annual General Meeting, May 19, 2026KORU Medical Systems, Inc., Annual General Meeting, May 19, 2026. Location: 100 corporate drive, mahwah, nj 07430, United StatesReported Earnings • Mar 15Full year 2025 earnings: EPS exceeds analyst expectationsFull year 2025 results: US$0.057 loss per share (improved from US$0.13 loss in FY 2024). Revenue: US$41.1m (up 22% from FY 2024). Net loss: US$2.64m (loss narrowed 56% from FY 2024). Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 9.1%. Revenue is forecast to grow 15% p.a. on average during the next 3 years, compared to a 7.9% growth forecast for the Medical Equipment industry in the US. Over the last 3 years on average, earnings per share has increased by 27% per year but the company’s share price has only increased by 4% per year, which means it is significantly lagging earnings growth.Price Target Changed • Mar 13Price target increased by 8.8% to US$6.80Up from US$6.25, the current price target is an average from 5 analysts. New target price is 59% above last closing price of US$4.28. Stock is up 55% over the past year. The company is forecast to post a net loss per share of US$0.03 next year compared to a net loss per share of US$0.081 last year.お知らせ • Mar 13+ 2 more updatesKoru Medical Systems Announces EU MDR Certification for Freedom60 Infusion Pump with Prefilled Syringe CompatibilityKORU Medical Systems, Inc. announced that its Freedom60 Infusion Pump, including adapter for use with 50 mL prefilled syringes, has achieved certification under the European Union Medical Devices Regulation (EU MDR 2017/745), enabling commercialization across the European Union. The Freedom60 Infusion Pump is designed to support dosing with 50 ml prefilled syringes, while the FreedomEDGE Infusion System provides a compatible option for 20 mL prefilled syringe formats. Together, these systems offer clinicians and patients flexibility across dosing regimens while maintaining a consistent, intuitive user experience. EU MDR certification of both the Freedom60 and FreedomEDGE Infusion Pumps expands access to a system designed to support the growing use of prefilled syringes in subcutaneous immunoglobulin (SCIg) therapy and simplify the home infusion experience for patients. The increasing availability of prefilled syringe formats represents an important step forward in the evolution of SCIg therapy. Published studies have shown that prefilled presentations can: Reduce preparation and administration step vs vials, Minimize medication handling, Decrease overall treatment burden, Improve patient confidence and independence with home therapy.お知らせ • Feb 27KORU Medical Systems, Inc. to Report Q4, 2025 Results on Mar 12, 2026KORU Medical Systems, Inc. announced that they will report Q4, 2025 results on Mar 12, 2026分析記事 • Feb 06Is There An Opportunity With KORU Medical Systems, Inc.'s (NASDAQ:KRMD) 49% Undervaluation?Key Insights The projected fair value for KORU Medical Systems is US$9.53 based on 2 Stage Free Cash Flow to Equity...お知らせ • Jan 30KORU Medical Systems Receives FDA 510(k) Clearance for Delivery of RYSTIGGO®? (rozanolixizumab-noli), Expanding Label for FreedomEDGE®? Infusion SystemKORU Medical Systems, Inc. announced that the Company received U.S. Food and Drug Administration (FDA) clearance for use of the KORU Medical FreedomEDGE®? infusion system to deliver RYSTIGGO®? (rozanolixizumab-noli), a therapy commercialized globally by UCB, Brussels, Belgium. The clearance for the FreedomEDGE®? label includes indicated administration by a healthcare professional, increasing flexibility and access for patients living with generalized myasthenia (gMG). RYSTIGGO®®? is a novel biologic approved to treat adults with generalized myasthenia gravis (gMG), a rare, chronic autoimmune disorder that affects communication between nerves and muscles. RYSTIGGO™? is administered as a weekly infusion of 3mL-6mL of drug over 15-30 minutes for 6 weeks, with subsequent treatment cycles based on clinical evaluation. KORU Medical's Freedom Infusion System enables, simplifies, and enhances the delivery of large-volume subcutaneous drugs. Supporting drug products with various requirements for viscosity, flow rate, and delivered drug volume from 5mL-50mL+, the Freedom System is market proven with: 15+ years of patient self-administration in the home; 45,000+ patients and over 2M infusions annually; 97% adherence rate and 9 on-label subcutaneous drugs distributed across 30+ countries.お知らせ • Dec 31KORU Medical Systems Announces 510(k) Submission for Clearance of the FreedomEDGE®? System with a Commercialized Oncology BiologicKORU Medical Systems, Inc. announced the submission of a 510(k) premarket notification to the U.S. Food and Drug Administration (FDA) seeking clearance for the use of KORU Medical's FreedomEDGE®? infusion system to subcutaneously administer PHESGO®? (pertuzumab/trastuzumab/hyaluronidase-zzxf), a co-formulated therapy for HER2+ breast cancer. The submission represents a key milestone in KORU Medical's strategy to expand the use of the FreedomEDGE®? system beyond its current immunoglobulin (Ig) indications and into the broader oncology infusion center market. The increasing shift from intravenous (IV) to subcutaneous (SC) drug delivery for cancer therapies allows for faster drug administration, reduced patient chair time, and aligns with a movement towards a more efficient care model. However, despite these advances, infusion centers continue to face unmet needs related to nursing satisfaction with drug administration, including workflow complexity associated with treatment protocol, time constraints for set up and physical discomfort for both patients and nurses during infusions. The FreedomEDGE®? system is designed to address these challenges by enabling consistent, controlled large-volume SC delivery while supporting more streamlined clinical workflows. KORU Medical anticipates a market entry upon FDA 510(k) clearance. KORU Medical's Freedom Infusion System enables, simplifies, and enhances the delivery of large-volume subcutaneous drugs. Supporting drug products with various requirements for viscosity, flow rate, and delivered drug volume, the Freedom System is market proven with: 15+ years on the market; 45,000+ patients and over 2M infusions annually; 97% adherence rate and 8 on-label Subcutaneous drugs across 30+ countries.Price Target Changed • Dec 22Price target increased by 11% to US$6.25Up from US$5.65, the current price target is an average from 5 analysts. New target price is approximately in line with last closing price of US$6.07. Stock is up 54% over the past year. The company is forecast to post a net loss per share of US$0.07 next year compared to a net loss per share of US$0.13 last year.分析記事 • Dec 17KORU Medical Systems, Inc.'s (NASDAQ:KRMD) Shares Climb 34% But Its Business Is Yet to Catch UpDespite an already strong run, KORU Medical Systems, Inc. ( NASDAQ:KRMD ) shares have been powering on, with a gain of...お知らせ • Dec 17KORU Medical Systems, Inc. Appoints Eric Schiller As Chief Technology Officer, Effective December 29, 2025KORU Medical Systems, Inc. appointed Eric Schiller as Chief Technology Officer, effective December 29, 2025. Eric joins KORU Medical with more than 25 years of leadership experience across research & development, device engineering, drug–device combination product development, supply chain strategy, and end-to-end product lifecycle management. He most recently served as Global Head of Device Development Portfolio at Sanofi, where he built and led a global team, advanced connected and reusable delivery platforms, drove multiple regulatory and launch-readiness initiatives, and oversaw more than 80 pipeline assets across Specialty Care, General Medicine and Vaccines. Prior to Sanofi, Eric spent more than a decade at Bristol-Myers Squibb and Celgene in roles spanning device development, biologics commercialization, and global product strategy, where he supported launches for major immunology and hematology assets including therapies requiring complex injection and infusion delivery systems, and implemented programs that improved reliability, patient adherence, and supply continuity. His earlier engineering career at Becton Dickinson and Saint-Gobain included development of next-generation syringe platforms and quality, safety, and process-improvement initiatives. Mr. Schiller holds an MBA with a management concentration from Seton Hall University and a Bachelor of Science in Mechanical Engineering from the New Jersey Institute of Technology. He is an inventor on more than a dozen U.S. patents in injection devices, safety systems, and drug-delivery components.Major Estimate Revision • Nov 19Consensus estimates of losses per share improve by 12%The consensus outlook for earnings per share (EPS) in fiscal year 2025 has improved. 2025 revenue forecast increased from US$39.9m to US$40.7m. EPS estimate increased from -US$0.08 per share to -US$0.07 per share. Medical Equipment industry in the US expected to see average net income growth of 15% next year. Consensus price target broadly unchanged at US$5.56. Share price rose 19% to US$4.45 over the past week.お知らせ • Nov 18KORU Medical Systems to Present Promising Results on the Use of the FreedomEDGE Syringe Infusion System in Infusion Centers at ESID/EHA/SIOPE Focused Symposium 2025KORU Medical Systems, Inc. announced that the Company will present its latest research at the ESID/EHA/SIOPE Focused Symposium 2025 in Vienna, Austria, November 18-20. The poster presentation, titled "Comparing Mechanical Pump and Manual Push for Short- duration Subcutaneous Infusions: A Nursing Preference Survey Study," highlights results from a multicenter evaluation conducted by KORU Medical across nine hospitals in Denmark. The study compared KORU Medical's FreedomEDGE Infusion System with traditional healthcare provider manual push techniques for short-duration subcutaneous infusions in oncology and immunology settings, evaluating nurse satisfaction, patient experience, usability, and workflow efficiency. The study results demonstrated: High nurse satisfaction - 91% found the system easier to use, 91% reported faster setup time, 81% experienced reduced hand strain, and 97% reported increased time for patient interaction; High patient satisfaction with 73% observing improved comfort; 97% of respondents would recommend the FreedomEDGE Infusions. The growing adoption of subcutaneous oncology therapies presents both an opportunity and a challenge for infusion centers worldwide. With nurse resources under increasing strain, the FreedomEDGE infusion System offers a scalable, hands-free alternative that maintains safety and patient comfort while improving workflow efficiency. KORU Medical anticipates filing a 510(k) submission to the FDA for use with a commercialized oncology drug in either the fourth quarter of 2025 or in the first quarter of 2026. KORU Medical's Freedom Syringe Infusion System enables, simplifies, and enhances the delivery of large-volume subcutaneous drugs. Supporting drug products with various requirements for viscosity, flow rate, and delivered drug volume from 5mL-50mL+, the Freedom System is market proven with: 15+ years of patient self-administration in the home; 45,000+ patients and over 2M infusions annually; 97% adherence rate and 8 on-label subcutaneous drugs; Distributed across 30+ countries. The ESID-EHA-SIOPE Symposium 2025 brings together experts from the European Society for Immunodeficiencies (ESID), the European Hematology Association (EHA), and the European Society for Paediatric Oncology (SIOPE) to provide a comprehensive platform for exploring how immunodeficiencies can influence hematologic and oncologic conditions and vice versa, how each specialty offers unique insights that contribute to improving diagnosis, treatment, and management strategies.Reported Earnings • Nov 14Third quarter 2025 earnings: EPS and revenues exceed analyst expectationsThird quarter 2025 results: US$0.017 loss per share (improved from US$0.034 loss in 3Q 2024). Revenue: US$10.4m (up 27% from 3Q 2024). Net loss: US$778.0k (loss narrowed 51% from 3Q 2024). Revenue exceeded analyst estimates by 7.6%. Earnings per share (EPS) also surpassed analyst estimates by 29%. Revenue is forecast to grow 16% p.a. on average during the next 3 years, compared to a 8.4% growth forecast for the Medical Equipment industry in the US. Over the last 3 years on average, earnings per share has increased by 16% per year and the company’s share price has also increased by 16% per year.お知らせ • Nov 13KORU Medical Systems, Inc. Revises Earnings Guidance for the Year 2025KORU Medical Systems, Inc. revised earnings guidance for the year 2025. The company is raising full year 2025 net revenues guidance to $40.5 million - $41.0 million, representing year-over-year growth of 20% - 22%, from prior range of $39.5 million - $40.5 million.お知らせ • Nov 05KORU Medical Systems, Inc. Announces Development Agreement for Innovation in Subcutaneous Immunoglobulin Infusion SystemsKORU Medical Systems, Inc. announced a development agreement with a global pharmaceutical company. The agreement allows for broad collaboration on next-generation infusion systems in subcutaneous immunoglobulin (SCIg) therapy for both commercial drugs and clinical programs. The agreement is for KORU Medical to support the qualification of an infusion system that can accommodate both vials and prefilled syringes (PFS). KORU Medical's Freedom60®? and FreedomEDGE®? infusion pumps were the first devices to be 510(k) cleared for use with prefilled syringes. The innovative system will be developed using KORU Medical's infusion technology along with SCHOTT TOPPAC®? polymer syringes. KORU Medical's FREEDOM Syringe Infusion System enables, simplifies, and enhances the delivery of large-volume subcutaneous drugs. Supporting drug products with various requirements for viscosity, flow rate, and delivered drug volume from 5mL-50mL+, the Freedom System is market proven with: 15+ years of patient self-administration in the home; 45,000+ patients and over 2M infusions annually; 97% adherence rate and 8 on-label subcutaneous drugs2; Distributed across 30+ countries.Buy Or Sell Opportunity • Oct 28Now 20% undervaluedOver the last 90 days, the stock has risen 15% to US$4.01. The fair value is estimated to be US$5.01, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 10% over the last 3 years. Earnings per share has grown by 5.4%. Revenue is forecast to grow by 35% in 2 years. Earnings are forecast to grow by 99% in the next 2 years.お知らせ • Oct 23KORU Medical Systems, Inc. to Report Q3, 2025 Results on Nov 12, 2025KORU Medical Systems, Inc. announced that they will report Q3, 2025 results on Nov 12, 2025Buy Or Sell Opportunity • Oct 13Now 21% undervaluedOver the last 90 days, the stock has risen 38% to US$4.07. The fair value is estimated to be US$5.13, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 10% over the last 3 years. Earnings per share has grown by 5.4%. Revenue is forecast to grow by 35% in 2 years. Earnings are forecast to grow by 99% in the next 2 years.Buy Or Sell Opportunity • Sep 22Now 21% undervaluedOver the last 90 days, the stock has risen 13% to US$4.02. The fair value is estimated to be US$5.11, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 10% over the last 3 years. Earnings per share has grown by 5.4%. Revenue is forecast to grow by 35% in 2 years. Earnings are forecast to grow by 99% in the next 2 years.Buy Or Sell Opportunity • Sep 05Now 20% undervaluedOver the last 90 days, the stock has risen 32% to US$4.06. The fair value is estimated to be US$5.10, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 10% over the last 3 years. Earnings per share has grown by 5.4%. Revenue is forecast to grow by 35% in 2 years. Earnings are forecast to grow by 99% in the next 2 years.分析記事 • Aug 14Investors Appear Satisfied With KORU Medical Systems, Inc.'s (NASDAQ:KRMD) Prospects As Shares Rocket 34%Despite an already strong run, KORU Medical Systems, Inc. ( NASDAQ:KRMD ) shares have been powering on, with a gain of...Reported Earnings • Aug 08Second quarter 2025 earnings released: US$0.004 loss per share (vs US$0.022 loss in 2Q 2024)Second quarter 2025 results: US$0.004 loss per share (improved from US$0.022 loss in 2Q 2024). Revenue: US$10.2m (up 21% from 2Q 2024). Net loss: US$206.9k (loss narrowed 79% from 2Q 2024). Revenue is forecast to grow 15% p.a. on average during the next 3 years, compared to a 8.3% growth forecast for the Medical Equipment industry in the US. Over the last 3 years on average, earnings per share has increased by 5% per year but the company’s share price has increased by 17% per year, which means it is tracking significantly ahead of earnings growth.New Risk • Aug 07New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of American stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (US$207k net loss in 2 years). Share price has been volatile over the past 3 months (11% average weekly change).お知らせ • Aug 07KORU Medical Systems, Inc. Raises Earnings Guidance for the Year 2025KORU Medical Systems, Inc. raising earnings guidance for the year 2025. For the year, the company raising full year 2025 revenue guidance to $39.5 - $40.5 million, representing growth of 18% - 20%, from prior range of $38.5 - $39.5 million.お知らせ • Jul 17KORU Medical Systems, Inc. to Report Q2, 2025 Results on Aug 06, 2025KORU Medical Systems, Inc. announced that they will report Q2, 2025 results on Aug 06, 2025お知らせ • Jul 08KORU Medical Systems Appoints Adam Kalbermatten as Chief Commercial Officer, Effective July 28, 2025KORU Medical Systems, Inc. announced the appointment of Adam Kalbermatten as Chief Commercial Officer, effective July 28, 2025. Adam brings over two decades of commercial leadership experience in the medical device and pharmaceutical industries, with a proven track record of scaling businesses, building high-performing teams, and delivering customer-focused innovation. As Chief Commercial Officer, he will oversee all aspects of KORU Medical’s global commercial strategy—including marketing, sales, market access, and pharmaceutical customer engagement. Adam joins KORU Medical from Becton Dickinson (BD), where he most recently served as Vice President and General Manager, Advanced Drug Delivery Systems, leading growth initiatives across the injectable drug delivery platform. Prior to BD, Adam served as Chief Executive Officer of ZebraSci, a specialized provider of analytical and drug device combination product development services to pharmaceutical companies, where he led a successful turnaround and growth strategy resulting in an eventual acquisition of the company by BD. He also held global leadership roles at Terumo Medical Corporation, including Worldwide Director of Marketing and Worldwide Director of Business Development, where he helped shape the company’s global drug delivery strategy. Adam holds a Bachelor of Engineering in Mechanical Engineering and a Master of Engineering in Engineering Management from Stevens Institute of Technology, and an MBA with concentrations in Finance and Healthcare from Columbia Business School.分析記事 • Jun 22Market Participants Recognise KORU Medical Systems, Inc.'s (NASDAQ:KRMD) Revenues Pushing Shares 27% HigherKORU Medical Systems, Inc. ( NASDAQ:KRMD ) shareholders would be excited to see that the share price has had a great...Board Change • Jun 01Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 5 experienced directors. 1 highly experienced director. Director Ed Wholihan was the last director to join the board, commencing their role in 2023. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Reported Earnings • May 10First quarter 2025 earnings: EPS in line with analyst expectations despite revenue beatFirst quarter 2025 results: US$0.025 loss per share (improved from US$0.042 loss in 1Q 2024). Revenue: US$9.64m (up 18% from 1Q 2024). Net loss: US$1.17m (loss narrowed 40% from 1Q 2024). Revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 8.1% growth forecast for the Medical Equipment industry in the US. Over the last 3 years on average, earnings per share has fallen by 7% per year but the company’s share price has increased by 15% per year, which means it is well ahead of earnings.New Risk • May 09New minor risk - ProfitabilityThe company is currently unprofitable and not forecast to become profitable over the next 2 years. Trailing 12-month net loss: US$6.1m Forecast net loss in 2 years: US$1.7m This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (US$1.7m net loss in 2 years). Share price has been volatile over the past 3 months (12% average weekly change).お知らせ • May 08Koru Medical Systems, Inc. Raises Earnings Guidance for Full Year 2025KORU Medical Systems, Inc. raised earnings guidance for full year 2025. For the period the company raising revenue guidance to $38.5 million to $39.5 million from prior range of $38.0 million to $39.0 million.分析記事 • May 08KORU Medical Systems, Inc. (NASDAQ:KRMD) Stocks Shoot Up 27% But Its P/S Still Looks ReasonableThose holding KORU Medical Systems, Inc. ( NASDAQ:KRMD ) shares would be relieved that the share price has rebounded...お知らせ • Apr 23KORU Medical Systems, Inc., Annual General Meeting, May 14, 2025KORU Medical Systems, Inc., Annual General Meeting, May 14, 2025. Location: 100 corporate drive, mahwah, nj 07495, United Statesお知らせ • Apr 17KORU Medical Systems, Inc. to Report Q1, 2025 Results on May 07, 2025KORU Medical Systems, Inc. announced that they will report Q1, 2025 results on May 07, 2025お知らせ • Apr 09KORU Medical Systems, Inc. Announces Executive ChangesOn April 3, 2025, Kenneth Miller resigned his employment and position as Chief Commercial Officer of KORU Medical Systems, Inc. (the “Company”), effective immediately, to pursue a Chief Executive Officer role at an organization that does not compete with the Company. KORU Medical would like to thank Mr. Miller for his contributions to the Company and recognize the instrumental role he played in establishing and implementing strategic commercial growth priorities during his tenure. Rob Cannon will lead the Company’s commercial operations for the Core business until a succeeding Chief Commercial Officer is named. Mr. Cannon has served as the Company’s Vice President of Sales for North America since November 2021 and has over 30 years of experience in sales across the healthcare industry, including11 years with McKesson, a healthcare supply chain management company specializing in providing pharmaceuticals and healthcare services across the globe, where he led the strategy, planning and implementation of sales, and marketing strategies focused on specialty pharma and home infusion channels. The Company has retained the services of an executive search firm to commence the search for a new Chief Commercial Officer.New Risk • Apr 08New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: US$98.3m This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. This is currently the only risk that has been identified for the company.Recent Insider Transactions Derivative • Mar 20President notifies of intention to sell stockLinda Tharby intends to sell 30k shares in the next 90 days after lodging an Intent To Sell Form on the 19th of March. If the sale is conducted around the recent share price of US$2.83, it would amount to US$85k. For the year to December 2021, Linda's total compensation was 79% salary and 21% non-salary. Since March 2024, Linda has owned 1.82m shares directly. There have been no trades via on-market transactions or options from company insiders in the last 12 months.Major Estimate Revision • Mar 19Consensus EPS estimates fall by 19%The consensus outlook for fiscal year 2025 has been updated. 2025 expected loss increased from -US$0.086 to -US$0.102 per share. Revenue forecast unchanged at US$38.4m. Medical Equipment industry in the US expected to see average net income growth of 18% next year. Consensus price target of US$5.70 unchanged from last update. Share price fell 11% to US$2.92 over the past week.Reported Earnings • Mar 13Full year 2024 earnings: Revenues and EPS in line with analyst expectationsFull year 2024 results: US$0.13 loss per share (improved from US$0.30 loss in FY 2023). Revenue: US$33.6m (up 18% from FY 2023). Net loss: US$6.07m (loss narrowed 56% from FY 2023). Revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 7.7% growth forecast for the Medical Equipment industry in the US. Over the last 3 years on average, earnings per share has fallen by 19% per year but the company’s share price has only fallen by 3% per year, which means it has not declined as severely as earnings.お知らせ • Mar 13KORU Medical Systems, Inc. Provides Earnings Guidance for the Full Year of 2025KORU Medical Systems, Inc. provided earnings guidance for the full year of 2025. For the full year of 2025, the company expects net revenues guidance of $38.0 - $39.0 million, representing growth of 13% - 16% over the prior year.分析記事 • Mar 05KORU Medical Systems, Inc.'s (NASDAQ:KRMD) Stock Retreats 27% But Revenues Haven't Escaped The Attention Of InvestorsKORU Medical Systems, Inc. ( NASDAQ:KRMD ) shares have had a horrible month, losing 27% after a relatively good period...お知らせ • Feb 20KORU Medical Systems, Inc. to Report Q4, 2024 Results on Mar 12, 2025KORU Medical Systems, Inc. announced that they will report Q4, 2024 results on Mar 12, 2025お知らせ • Jan 31KORU Medical Systems Announces Phase III Clinical Trial Collaboration for a New Drug Indication in NephrologyKORU Medical Systems announced a collaboration with a global pharmaceutical manufacturer on a Phase III clinical trial for an expanded indication of a commercialized drug therapy. The expanded indication is intended to treat a rare renal disorder in a population of approximately 30,000 patients with a projected 300,000 annual infusions. This announcement highlights an additional collaboration between KORU Medical and its partners in the development of novel therapies and enhanced drug delivery experiences for patients living with rare conditions. The Phase III trial aims to assess the safety, efficacy, and performance of the drug to treat patients with complications from kidney transplants.お知らせ • Jan 16KORU Medical Systems, Inc. Announces Preliminary Unaudited Revenues Guidance for the Fourth Quarter and Full Year Ended December 31, 2024KORU Medical Systems, Inc. announced preliminary unaudited revenues guidance for the fourth quarter and full year ended December 31, 2024. Preliminary, unaudited fourth quarter 2024 net revenues expected to be $8.9 million, representing growth of 23% over the prior year period. Preliminary, unaudited full year 2024 net revenues expected to be $33.7 million, representing growth of 18% over the prior year.分析記事 • Nov 16KORU Medical Systems, Inc. (NASDAQ:KRMD) Released Earnings Last Week And Analysts Lifted Their Price Target To US$4.10As you might know, KORU Medical Systems, Inc. ( NASDAQ:KRMD ) just kicked off its latest quarterly results with some...Reported Earnings • Nov 15Third quarter 2024 earnings: EPS and revenues exceed analyst expectationsThird quarter 2024 results: US$0.034 loss per share (further deteriorated from US$0.03 loss in 3Q 2023). Revenue: US$8.18m (up 17% from 3Q 2023). Net loss: US$1.58m (loss widened 16% from 3Q 2023). Revenue exceeded analyst estimates by 6.1%. Earnings per share (EPS) also surpassed analyst estimates by 10.0%. Revenue is forecast to grow 15% p.a. on average during the next 3 years, compared to a 8.2% growth forecast for the Medical Equipment industry in the US. Over the last 3 years on average, earnings per share has fallen by 32% per year but the company’s share price has only fallen by 2% per year, which means it has not declined as severely as earnings.Price Target Changed • Nov 14Price target increased by 17% to US$4.10Up from US$3.50, the current price target is an average from 5 analysts. New target price is 33% above last closing price of US$3.08. Stock is up 40% over the past year. The company is forecast to post a net loss per share of US$0.13 next year compared to a net loss per share of US$0.30 last year.お知らせ • Nov 14KORU Medical Systems, Inc. Raises Earnings Guidance for the Full Year 2024KORU Medical Systems, Inc. raised earnings guidance for the full year 2024. For the full year, the company expects net revenue to be in the range of $32.75 million to $33.25 million, representing growth of 15% to 17%; increased from previously issued guidance of $32.0 to $32.5 million, or 12% to 14%.Seeking Alpha • Nov 06Impressive Turnaround At KORU MedicalSummary KORU Medical Systems is poised for growth with solid revenue increases, multiple growth drivers, and a chance to reach cash flow breakeven in Q4. The FREEDOM system, designed for at-home drug delivery, offers recurring revenue from consumables and is gaining market share in the SCIg market. International expansion and novel therapies present significant growth opportunities, with international revenue growing 46% and novel therapies progressing to Phase 3 trials. Financials are improving with a 22% revenue increase, 65% gross margin, and expected cash flow breakeven in Q4, making the shares a solid buy here. Read the full article on Seeking Alphaお知らせ • Oct 24KORU Medical Systems, Inc. to Report Q3, 2024 Results on Nov 13, 2024KORU Medical Systems, Inc. announced that they will report Q3, 2024 results on Nov 13, 2024分析記事 • Aug 29We're Interested To See How KORU Medical Systems (NASDAQ:KRMD) Uses Its Cash Hoard To GrowThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...Major Estimate Revision • Aug 14Consensus estimates of losses per share improve by 20%The consensus outlook for earnings per share (EPS) in fiscal year 2024 has improved. 2024 revenue forecast increased from US$31.8m to US$32.2m. EPS estimate increased from -US$0.166 per share to -US$0.133 per share. Medical Equipment industry in the US expected to see average net income growth of 17% next year. Consensus price target up from US$3.50 to US$3.60. Share price rose 8.5% to US$2.31 over the past week.New Risk • Aug 08New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: US$97.5m This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (US$3.1m net loss in 2 years). Market cap is less than US$100m (US$97.5m market cap).Reported Earnings • Aug 08Second quarter 2024 earnings: EPS and revenues exceed analyst expectationsSecond quarter 2024 results: US$0.022 loss per share (improved from US$0.055 loss in 2Q 2023). Revenue: US$8.43m (up 22% from 2Q 2023). Net loss: US$988.7k (loss narrowed 60% from 2Q 2023). Revenue exceeded analyst estimates by 11%. Earnings per share (EPS) also surpassed analyst estimates by 52%. Revenue is forecast to grow 15% p.a. on average during the next 3 years, compared to a 8.2% growth forecast for the Medical Equipment industry in the US. Over the last 3 years on average, earnings per share has fallen by 38% per year but the company’s share price has only fallen by 11% per year, which means it has not declined as severely as earnings.お知らせ • Aug 08KORU Medical Systems, Inc. Revises Revenue Guidance for the Full Year 2024KORU Medical Systems, Inc. revised revenue guidance for the full year 2024. Raising full year 2024 net revenue guidance to $32.0 - $32.5, representing growth of 12-14%; increased from previously issued guidance of $31.2 - $32.2 million, or 10% to 13%. Raising full year 2024 gross margin guidance to 61% - 62%; increased from previously issued guidance of 59% - 61%.分析記事 • Jul 30KORU Medical Systems, Inc. (NASDAQ:KRMD) Doing What It Can To Lift SharesWith a median price-to-sales (or "P/S") ratio of close to 3.2x in the Medical Equipment industry in the United States...お知らせ • Jul 25KORU Medical Systems, Inc Announces Executive ChangesKORU Medical Systems, Inc. announced the promotion of Christopher Pazdan, to Chief Operating Officer, effective July 18, 2024. Mr. Pazdan has been with the organization since 2021, and last served as the Company’s Senior Vice President of Operations overseeing Quality, Regulatory, Operations, Supply Chain and Project Management. In his role as COO, Chris will also oversee the Research and Development organization and be responsible for the Company’s product development pipeline and innovation efforts. Chris joined KORU Medical Systems in 2021, as Vice President of Quality Assurance and Regulatory Affairs. In 2022, he was promoted to Senior Vice President of Operations, which included leading manufacturing, supply chain and the project management office. Chris brings more than 20 years of experience in the medical device industry including leadership roles at Hill-Rom and Becton Dickinson (formerly CareFusion/Cardinal Health) across a variety of strategic functions and roles. As part of this transition, Brian Case, Chief Technology Officer, will be leaving the Company on September 16, 2024.お知らせ • Jul 18KORU Medical Systems, Inc. to Report Q2, 2024 Results on Aug 07, 2024KORU Medical Systems, Inc. announced that they will report Q2, 2024 results at 4:00 PM, US Eastern Standard Time on Aug 07, 2024お知らせ • Jul 03+ 3 more updatesKORU Medical Systems, Inc.(NasdaqCM:KRMD) dropped from Russell Small Cap Comp Growth IndexKORU Medical Systems, Inc.(NasdaqCM:KRMD) dropped from Russell Small Cap Comp Growth Indexお知らせ • Jul 02KORU Medical Systems Receives Regulatory Clearance for FreedomEdge Infusion System in JapanKORU Medical Systems, Inc. announced that its FreedomEdge System has received regulatory clearance in Japan for the delivery of multiple drugs, including CSL Behring's Hizentra subcutaneous immunoglobulin (SCIg), Takeda Pharmaceutical's Cuvitru SCIg, and Sobi's Aspaveli paroxysmal nocturnal hemoglobinuria (PNH). The regulatory milestone marks a significant advancement in patient care in Japan, providing patients and healthcare providers with access to cutting-edge treatment options for Subcutaneous Immunoglobulin therapy (SCIg) and Paroxysmal Nocturnal Hemoglobinuria (PNH). the FreedomEdge System, known for its reliability, precision, and patient-friendly design, offers convenient and efficient administration of large volume subcutaneous therapies at home and in the clinic. The FreedomEdge System is designed to meet the diverse needs of patients and healthcare professionals, offering customizable features for personalized treatment experiences. Its compact and portable design allows for flexibility in treatment administration, enabling patients to manage their therapy effectively in various settings.お知らせ • Jun 06KORU Medical Systems, Inc. Announces Collaboration with Global Pharmaceutical Company to Initiate Feasibility Study with Its Freedom Infusion System for FDA and EMA Approved Subcutaneous Oncology Biologic DrugKORU Medical Systems, Inc. announced a collaboration with a global pharmaceutical company to initiate a feasibility study with KORU Medical’s Freedom Infusion System for an FDA and EMA approved subcutaneous oncology biologic drug, that is currently being delivered via a manual syringe administration by a healthcare professional. The Freedom System is a purely mechanical ambulatory drug delivery device with 11 drugs approved on the label and over 40,000 patients globally. The system is designed to deliver large volumes of biologic medications from 2mL to over 100mL subcutaneously. The Freedom System is capable of allowing patients to self-administer their therapy at home and/or by healthcare professionals in a clinic setting.Major Estimate Revision • May 08Consensus EPS estimates fall by 15%The consensus outlook for fiscal year 2024 has been updated. 2024 expected loss increased from -US$0.137 to -US$0.158 per share. Revenue forecast unchanged at US$31.8m. Medical Equipment industry in the US expected to see average net income growth of 18% next year. Consensus price target of US$3.50 unchanged from last update. Share price rose 4.1% to US$2.26 over the past week.お知らせ • May 03KORU Medical Systems, Inc. reaffirms Financial Guidance for the Full Year of 2024·KORU Medical Systems, Inc. reaffirmed financial guidance for the full year of 2024. For the period, the company expects net revenue between $31.2 and $32.2 million, representing growth of 10% to 13% over the prior year.Reported Earnings • May 02First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behindFirst quarter 2024 results: US$0.042 loss per share (improved from US$0.053 loss in 1Q 2023). Revenue: US$8.20m (up 11% from 1Q 2023). Net loss: US$1.94m (loss narrowed 20% from 1Q 2023). Revenue exceeded analyst estimates by 8.8%. Earnings per share (EPS) missed analyst estimates by 14%. Revenue is forecast to grow 15% p.a. on average during the next 3 years, compared to a 8.1% growth forecast for the Medical Equipment industry in the US. Over the last 3 years on average, earnings per share has fallen by 43% per year but the company’s share price has only fallen by 12% per year, which means it has not declined as severely as earnings.お知らせ • Apr 19KORU Medical Systems, Inc. to Report Q1, 2024 Results on May 01, 2024KORU Medical Systems, Inc. announced that they will report Q1, 2024 results on May 01, 2024お知らせ • Mar 29KORU Medical Systems, Inc., Annual General Meeting, May 09, 2024KORU Medical Systems, Inc., Annual General Meeting, May 09, 2024, at 08:00 Eastern Daylight. Location: 100 Corporate Drive, Mahwah New Jersey United States Agenda: To consider election of directors; to consider Advisory approval of the compensation of the Company’s executive officers; to consider ratification of the appointment of independent registered public accountants; to consider approval of the 2024 Omnibus Equity Incentive plan; and to consider transaction of any other business that may properly come before the meeting.Reported Earnings • Mar 14Full year 2023 earnings: EPS misses analyst expectationsFull year 2023 results: US$0.30 loss per share (further deteriorated from US$0.19 loss in FY 2022). Revenue: US$28.5m (up 2.2% from FY 2022). Net loss: US$13.7m (loss widened 59% from FY 2022). Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 67%. Revenue is forecast to grow 16% p.a. on average during the next 3 years, compared to a 7.8% growth forecast for the Medical Equipment industry in the US. Over the last 3 years on average, earnings per share has fallen by 48% per year but the company’s share price has only fallen by 16% per year, which means it has not declined as severely as earnings.お知らせ • Mar 14KORU Medical Systems, Inc. Provides Earnings Guidance for the Full Year 2024KORU Medical Systems, Inc. provided earnings guidance for the full year 2024. For the year, the company expected net revenue between $31.2 and $32.2 million, representing growth in the range of 10% to 13%.お知らせ • Mar 12KORU Medical Systems, Inc. Announces A Feasibility Study to Enter Ambulatory Infusion Settings with A Commercialized BiologicKORU Medical Systems, Inc. announced a collaboration with a global pharmaceutical manufacturer to initiate a feasibility study with KORU's Freedom Infusion System for an already commercialized rare disease therapy. Upon successful completion of the feasibility study, KORU Medical intends to develop a customized Freedom System that will deliver this large volume therapy via subcutaneous administration. Healthcare providers administer this rare disease drug in the growing ambulatory infusion center (AIC) and ambulatory infusion suite (AIS) setting in the United States and the hospital setting in the European Union.お知らせ • Feb 22KORU Medical Systems, Inc. to Report Q4, 2023 Results on Mar 13, 2024KORU Medical Systems, Inc. announced that they will report Q4, 2023 results on Mar 13, 2024分析記事 • Feb 15Market Cool On KORU Medical Systems, Inc.'s (NASDAQ:KRMD) RevenuesThere wouldn't be many who think KORU Medical Systems, Inc.'s ( NASDAQ:KRMD ) price-to-sales (or "P/S") ratio of 3.6x...Major Estimate Revision • Nov 15Consensus EPS estimates upgraded to US$0.18 loss, revenue downgradedThe consensus outlook for fiscal year 2023 has been updated. 2023 revenue forecast fell from US$31.0m to US$28.2m. 2023 losses expected to reduce from -US$0.206 to -US$0.178 per share. Medical Equipment industry in the US expected to see average net income growth of 25% next year. Consensus price target down from US$4.30 to US$3.80. Share price was steady at US$2.30 over the past week.お知らせ • Nov 11Koru Medical Systems, Inc. Appoints Kenneth Miller as Chief Commercial OfficerKenneth Miller, age 55, has been appointed by KORU Medical Systems, Inc. (the “Company”) to serve in the newly created position of Chief Commercial Officer commencing November 6, 2023. Mr. Miller brings over 30 years of experience in leading teams in commercialization and marketing strategy and international expansion. Mr. Miller served as President and CEO of NASCO Healthcare Inc. from 2018 to January 2023. Prior to that, Mr. Miller served in various roles at Becton Dickinson from 2011 to 2018 with his last role as the Worldwide President Diabetes Care. He also held leadership roles in marketing, sales, and business development with Novo Nordisk Inc., Adams Respiratory Therapeutics, Inc., and Roche Laboratories. Mr. Miller earned his Bachelor of Arts in Business Management from State University of New York at Albany and his Master of Business Administration from The University of Chicago, Booth School of Business.New Risk • Nov 10New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: US$99.9m This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (US$5.6m net loss in 2 years). Market cap is less than US$100m (US$99.9m market cap).Reported Earnings • Nov 10Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behindThird quarter 2023 results: US$0.03 loss per share (further deteriorated from US$0.027 loss in 3Q 2022). Revenue: US$7.00m (down 9.8% from 3Q 2022). Net loss: US$1.37m (loss widened 12% from 3Q 2022). Revenue missed analyst estimates by 12%. Earnings per share (EPS) exceeded analyst estimates by 40%. Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 7.8% growth forecast for the Medical Equipment industry in the US. Over the last 3 years on average, earnings per share has fallen by 51% per year but the company’s share price has only fallen by 19% per year, which means it has not declined as severely as earnings.お知らせ • Nov 08KORU Medical Systems, Inc. Receives FDA 510(k) Clearance for FREEDOM60 Infusion System With Hizentra 50 ML Prefilled SyringesKORU Medical Systems, Inc. announced that it received U.S. Food and Drug Administration (FDA) clearance for use of the FREEDOM60(R) Infusion System with Hizentra(R) 50 mL prefilled syringes (PFS). The FREEDOM(TM) Infusion System is the first and only infusion system cleared for use with prefilled syringes and, given the majority of patients are prescribed doses of 50 mL or greater, this clearance for FREEDOM60(R) significantly expands the benefits of PFS use, especially for those diagnosed with conditions requiring significantly higher doses of immunoglobulin. When using prefilled syringes with the FREEDOM(TM) Infusion System, KORU Medical has demonstrated that patients can experience up to an 80% reduction in drug preparation tasks when compared to using vials. The FDA approved the Hizentra(R) 50 mL prefilled syringe in April 2023, and CSL Behring has announced an early 2024 availability. Hizentra(R) is the most prescribed subcutaneous immunoglobulin and the first to be available in prefilled syringes.お知らせ • Oct 26KORU Medical Systems, Inc. to Report Q3, 2023 Results on Nov 08, 2023KORU Medical Systems, Inc. announced that they will report Q3, 2023 results on Nov 08, 2023Board Change • Oct 13High number of new directorsThere are 5 new directors who have joined the board in the last 3 years. Director Ed Wholihan was the last director to join the board, commencing their role in 2023. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.分析記事 • Sep 21We're Hopeful That KORU Medical Systems (NASDAQ:KRMD) Will Use Its Cash WiselyThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...Reported Earnings • Aug 10Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behindSecond quarter 2023 results: US$0.055 loss per share (improved from US$0.065 loss in 2Q 2022). Revenue: US$6.94m (up 5.9% from 2Q 2022). Net loss: US$2.50m (loss narrowed 15% from 2Q 2022). Revenue missed analyst estimates by 4.0%. Earnings per share (EPS) exceeded analyst estimates by 12%. Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 7.8% growth forecast for the Medical Equipment industry in the US. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 27 percentage points per year, which is a significant difference in performance.お知らせ • Aug 10KORU Medical Systems, Inc. Updates Revenue Guidance for the Full Year 2023KORU Medical Systems, Inc. updated revenue guidance for the full year 2023. For the year, the company reducing net revenue guidance to $31.0 million - $32.5 million, representing growth in the range of 11%-17% from prior guidance of $32.5 million - $33.5 million, representing growth in the range of 17-20%.Price Target Changed • Aug 03Price target decreased by 10% to US$4.33Down from US$4.83, the current price target is an average from 3 analysts. New target price is 70% above last closing price of US$2.55. Stock is down 5.6% over the past year. The company is forecast to post a net loss per share of US$0.20 next year compared to a net loss per share of US$0.19 last year.お知らせ • Aug 03+ 1 more updateKORU Medical Systems, Inc. Provides Revenue Guidance for the Full Year 2023KORU Medical Systems, Inc. provided revenue guidance for the full year 2023. For the year, the company net revenues are now expected to be between $31 million and $32.5 million, representing revenue growth in the range of 11%-17% from the prior year.お知らせ • Aug 01KORU Medical Systems, Inc. to Report Q2, 2023 Results on Aug 09, 2023KORU Medical Systems, Inc. announced that they will report Q2, 2023 results on Aug 09, 2023分析記事 • Jul 14Market Cool On KORU Medical Systems, Inc.'s (NASDAQ:KRMD) Earnings Pushing Shares 28% LowerKORU Medical Systems, Inc. ( NASDAQ:KRMD ) shareholders that were waiting for something to happen have been dealt a...お知らせ • Jul 11KORU Medical Systems, Inc. Announces 510(K) Submission for Freedom60®? Infusion System with Hizentra®? 50 Ml Preilled SyringesKORU Medical Systems, Inc. announced that it has submitted a 510(k) premarket notification submission to the U.S. Food and Drug Administration for the use of its FREEDOM60®? Infusion System with Hizentra®? 50 mL prefilled syringes. The FDA approved the 50 mL Hizentra prefilled syringe in April 2023. Hizentra is the most prescribed subcutaneous immunoglobulin and the first to be available in prefilled syringes.業績と収益の成長予測NasdaqCM:KRMD - アナリストの将来予測と過去の財務データ ( )USD Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数12/31/202864589112/31/202757245512/31/202649-21253/31/202643-201N/A12/31/202541-300N/A9/30/202539-400N/A6/30/202537-5-2-1N/A3/31/202535-5-20N/A12/31/202434-6-20N/A9/30/202432-12-20N/A6/30/202431-12-10N/A3/31/202429-13-1-1N/A12/31/202329-14-6-5N/A9/30/202329-8-5-5N/A6/30/202329-8-7-6N/A3/31/202329-9-11-8N/A12/31/202228-9-8-5N/A9/30/202227-8-10-7N/A6/30/202225-8-8-6N/A3/31/202224-6-4-3N/A12/31/202123-5-5-4N/A9/30/202121-4-6-5N/A6/30/202121-3-7-6N/A3/31/202123-3-4-4N/A12/31/202024-1-2-1N/A9/30/202026012N/A6/30/202027045N/A3/31/202025112N/A12/31/2019231N/A0N/A9/30/2019210N/A0N/A6/30/2019190N/A-1N/A3/31/2019180N/A0N/A12/31/2018171N/A1N/A9/30/2018182N/A2N/A6/30/2018172N/A2N/A3/31/2018161N/A1N/A12/31/2017161N/A1N/A2/28/201712-1N/A0N/A11/30/2016130N/A1N/A8/31/2016130N/A1N/A5/31/2016131N/A2N/A2/29/2016121N/A2N/A11/30/2015121N/A1N/A8/31/2015121N/A1N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: KRMDは今後 3 年間で収益性が向上すると予測されており、これは 貯蓄率 ( 3.5% ) よりも高い成長率であると考えられます。収益対市場: KRMD今後 3 年間で収益性が向上すると予想されており、これは市場平均を上回る成長と考えられます。高成長収益: KRMD今後 3 年以内に収益を上げることが予想されます。収益対市場: KRMDの収益 ( 14.6% ) US市場 ( 12.5% ) よりも速いペースで成長すると予測されています。高い収益成長: KRMDの収益 ( 14.6% ) 20%よりも低い成長が予測されています。一株当たり利益成長率予想将来の株主資本利益率将来のROE: KRMDの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YHealthcare 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/07/31 11:57終値2026/07/31 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋KORU Medical Systems, Inc. 5 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。7 アナリスト機関Anderson SchockB. Riley Securities, Inc.Caitlin CroninCanaccord Genuitynull nullCG Capital4 その他のアナリストを表示
Price Target Changed • Mar 13Price target increased by 8.8% to US$6.80Up from US$6.25, the current price target is an average from 5 analysts. New target price is 59% above last closing price of US$4.28. Stock is up 55% over the past year. The company is forecast to post a net loss per share of US$0.03 next year compared to a net loss per share of US$0.081 last year.
Price Target Changed • Dec 22Price target increased by 11% to US$6.25Up from US$5.65, the current price target is an average from 5 analysts. New target price is approximately in line with last closing price of US$6.07. Stock is up 54% over the past year. The company is forecast to post a net loss per share of US$0.07 next year compared to a net loss per share of US$0.13 last year.
Major Estimate Revision • Nov 19Consensus estimates of losses per share improve by 12%The consensus outlook for earnings per share (EPS) in fiscal year 2025 has improved. 2025 revenue forecast increased from US$39.9m to US$40.7m. EPS estimate increased from -US$0.08 per share to -US$0.07 per share. Medical Equipment industry in the US expected to see average net income growth of 15% next year. Consensus price target broadly unchanged at US$5.56. Share price rose 19% to US$4.45 over the past week.
お知らせ • Nov 13KORU Medical Systems, Inc. Revises Earnings Guidance for the Year 2025KORU Medical Systems, Inc. revised earnings guidance for the year 2025. The company is raising full year 2025 net revenues guidance to $40.5 million - $41.0 million, representing year-over-year growth of 20% - 22%, from prior range of $39.5 million - $40.5 million.
お知らせ • Aug 07KORU Medical Systems, Inc. Raises Earnings Guidance for the Year 2025KORU Medical Systems, Inc. raising earnings guidance for the year 2025. For the year, the company raising full year 2025 revenue guidance to $39.5 - $40.5 million, representing growth of 18% - 20%, from prior range of $38.5 - $39.5 million.
お知らせ • May 08Koru Medical Systems, Inc. Raises Earnings Guidance for Full Year 2025KORU Medical Systems, Inc. raised earnings guidance for full year 2025. For the period the company raising revenue guidance to $38.5 million to $39.5 million from prior range of $38.0 million to $39.0 million.
お知らせ • Jul 16KORU Medical Systems, Inc. to Report Q2, 2026 Results on Aug 05, 2026KORU Medical Systems, Inc. announced that they will report Q2, 2026 results on Aug 05, 2026
ナラティブ更新 • Jun 26KRMD: Increasing Home Infusion Adoption Will Support Higher Future Earnings PowerAnalysts have raised their fair value estimate for KORU Medical Systems to $5.00 from $4.00, reflecting updated assumptions regarding revenue growth, profit margins, and a lower future P/E multiple in their valuation work. What's in the News KORU Medical Systems presented new research at the Oncology Nursing Society Congress, highlighting its FreedomEDGE infusion system in subcutaneous monoclonal antibody administration across four U.S. community infusion centers, source: company key developments.
お知らせ • May 20Koru Medical Systems Presents Real World Data on the Benefits of the Freedomedge Syringe Infusion SystemKORU Medical Systems, Inc. presented its latest research at the Oncology Nursing Society Congress, May 13-17. The poster at ONS was titled, “Reducing Ergonomic Strain During Subcutaneous Monoclonal Antibody Administration.” The ONS abstract evaluated nursing workflow, nurse experience, and patient-reported outcomes after implementing KORU Medical's FreedomEDGE infusion system for subcutaneous drug administration across four community infusion centers in the United States. The findings demonstrated: Efficiency- 100% of doses successfully administered with infusion times aligned with clinical guidelines. Reduced Strain- Nurses experienced significantly less strain after implementing pump assisted or tubing-needle set assisted drug administration. High Satisfaction- Both nurses (4.85/5) and patients (4.92/5) reported high satisfaction levels. Workflow advantages- Nurses reported ability to multitask during 80% of pump infusions. KORU Medical’s FREEDOM Syringe Infusion System enables, simplifies, and enhances the delivery of large-volume subcutaneous drugs. Supporting drug products with various requirements for viscosity, flow rate, and delivered drug volume from 5mL-50mL+, the Freedom System is market proven with: 15+ years of patient self-administration in the home. 59,000+ patients and over 3M infusions annually. 97% adherence rate and 9 on-label subcutaneous drugs. Approval in 30+ countries.
Reported Earnings • May 07First quarter 2026 earnings released: US$0.017 loss per share (vs US$0.025 loss in 1Q 2025)First quarter 2026 results: US$0.017 loss per share (improved from US$0.025 loss in 1Q 2025). Revenue: US$11.8m (up 22% from 1Q 2025). Net loss: US$807.1k (loss narrowed 31% from 1Q 2025). Revenue is forecast to grow 15% p.a. on average during the next 3 years, compared to a 8.0% growth forecast for the Medical Equipment industry in the US. Over the last 3 years on average, earnings per share has increased by 38% per year but the company’s share price has only increased by 4% per year, which means it is significantly lagging earnings growth.
お知らせ • Apr 16KORU Medical Systems, Inc. to Report Q1, 2026 Results on May 06, 2026KORU Medical Systems, Inc. announced that they will report Q1, 2026 results on May 06, 2026
お知らせ • Apr 10KORU Medical Systems, Inc., Annual General Meeting, May 19, 2026KORU Medical Systems, Inc., Annual General Meeting, May 19, 2026. Location: 100 corporate drive, mahwah, nj 07430, United States
Reported Earnings • Mar 15Full year 2025 earnings: EPS exceeds analyst expectationsFull year 2025 results: US$0.057 loss per share (improved from US$0.13 loss in FY 2024). Revenue: US$41.1m (up 22% from FY 2024). Net loss: US$2.64m (loss narrowed 56% from FY 2024). Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 9.1%. Revenue is forecast to grow 15% p.a. on average during the next 3 years, compared to a 7.9% growth forecast for the Medical Equipment industry in the US. Over the last 3 years on average, earnings per share has increased by 27% per year but the company’s share price has only increased by 4% per year, which means it is significantly lagging earnings growth.
Price Target Changed • Mar 13Price target increased by 8.8% to US$6.80Up from US$6.25, the current price target is an average from 5 analysts. New target price is 59% above last closing price of US$4.28. Stock is up 55% over the past year. The company is forecast to post a net loss per share of US$0.03 next year compared to a net loss per share of US$0.081 last year.
お知らせ • Mar 13+ 2 more updatesKoru Medical Systems Announces EU MDR Certification for Freedom60 Infusion Pump with Prefilled Syringe CompatibilityKORU Medical Systems, Inc. announced that its Freedom60 Infusion Pump, including adapter for use with 50 mL prefilled syringes, has achieved certification under the European Union Medical Devices Regulation (EU MDR 2017/745), enabling commercialization across the European Union. The Freedom60 Infusion Pump is designed to support dosing with 50 ml prefilled syringes, while the FreedomEDGE Infusion System provides a compatible option for 20 mL prefilled syringe formats. Together, these systems offer clinicians and patients flexibility across dosing regimens while maintaining a consistent, intuitive user experience. EU MDR certification of both the Freedom60 and FreedomEDGE Infusion Pumps expands access to a system designed to support the growing use of prefilled syringes in subcutaneous immunoglobulin (SCIg) therapy and simplify the home infusion experience for patients. The increasing availability of prefilled syringe formats represents an important step forward in the evolution of SCIg therapy. Published studies have shown that prefilled presentations can: Reduce preparation and administration step vs vials, Minimize medication handling, Decrease overall treatment burden, Improve patient confidence and independence with home therapy.
お知らせ • Feb 27KORU Medical Systems, Inc. to Report Q4, 2025 Results on Mar 12, 2026KORU Medical Systems, Inc. announced that they will report Q4, 2025 results on Mar 12, 2026
分析記事 • Feb 06Is There An Opportunity With KORU Medical Systems, Inc.'s (NASDAQ:KRMD) 49% Undervaluation?Key Insights The projected fair value for KORU Medical Systems is US$9.53 based on 2 Stage Free Cash Flow to Equity...
お知らせ • Jan 30KORU Medical Systems Receives FDA 510(k) Clearance for Delivery of RYSTIGGO®? (rozanolixizumab-noli), Expanding Label for FreedomEDGE®? Infusion SystemKORU Medical Systems, Inc. announced that the Company received U.S. Food and Drug Administration (FDA) clearance for use of the KORU Medical FreedomEDGE®? infusion system to deliver RYSTIGGO®? (rozanolixizumab-noli), a therapy commercialized globally by UCB, Brussels, Belgium. The clearance for the FreedomEDGE®? label includes indicated administration by a healthcare professional, increasing flexibility and access for patients living with generalized myasthenia (gMG). RYSTIGGO®®? is a novel biologic approved to treat adults with generalized myasthenia gravis (gMG), a rare, chronic autoimmune disorder that affects communication between nerves and muscles. RYSTIGGO™? is administered as a weekly infusion of 3mL-6mL of drug over 15-30 minutes for 6 weeks, with subsequent treatment cycles based on clinical evaluation. KORU Medical's Freedom Infusion System enables, simplifies, and enhances the delivery of large-volume subcutaneous drugs. Supporting drug products with various requirements for viscosity, flow rate, and delivered drug volume from 5mL-50mL+, the Freedom System is market proven with: 15+ years of patient self-administration in the home; 45,000+ patients and over 2M infusions annually; 97% adherence rate and 9 on-label subcutaneous drugs distributed across 30+ countries.
お知らせ • Dec 31KORU Medical Systems Announces 510(k) Submission for Clearance of the FreedomEDGE®? System with a Commercialized Oncology BiologicKORU Medical Systems, Inc. announced the submission of a 510(k) premarket notification to the U.S. Food and Drug Administration (FDA) seeking clearance for the use of KORU Medical's FreedomEDGE®? infusion system to subcutaneously administer PHESGO®? (pertuzumab/trastuzumab/hyaluronidase-zzxf), a co-formulated therapy for HER2+ breast cancer. The submission represents a key milestone in KORU Medical's strategy to expand the use of the FreedomEDGE®? system beyond its current immunoglobulin (Ig) indications and into the broader oncology infusion center market. The increasing shift from intravenous (IV) to subcutaneous (SC) drug delivery for cancer therapies allows for faster drug administration, reduced patient chair time, and aligns with a movement towards a more efficient care model. However, despite these advances, infusion centers continue to face unmet needs related to nursing satisfaction with drug administration, including workflow complexity associated with treatment protocol, time constraints for set up and physical discomfort for both patients and nurses during infusions. The FreedomEDGE®? system is designed to address these challenges by enabling consistent, controlled large-volume SC delivery while supporting more streamlined clinical workflows. KORU Medical anticipates a market entry upon FDA 510(k) clearance. KORU Medical's Freedom Infusion System enables, simplifies, and enhances the delivery of large-volume subcutaneous drugs. Supporting drug products with various requirements for viscosity, flow rate, and delivered drug volume, the Freedom System is market proven with: 15+ years on the market; 45,000+ patients and over 2M infusions annually; 97% adherence rate and 8 on-label Subcutaneous drugs across 30+ countries.
Price Target Changed • Dec 22Price target increased by 11% to US$6.25Up from US$5.65, the current price target is an average from 5 analysts. New target price is approximately in line with last closing price of US$6.07. Stock is up 54% over the past year. The company is forecast to post a net loss per share of US$0.07 next year compared to a net loss per share of US$0.13 last year.
分析記事 • Dec 17KORU Medical Systems, Inc.'s (NASDAQ:KRMD) Shares Climb 34% But Its Business Is Yet to Catch UpDespite an already strong run, KORU Medical Systems, Inc. ( NASDAQ:KRMD ) shares have been powering on, with a gain of...
お知らせ • Dec 17KORU Medical Systems, Inc. Appoints Eric Schiller As Chief Technology Officer, Effective December 29, 2025KORU Medical Systems, Inc. appointed Eric Schiller as Chief Technology Officer, effective December 29, 2025. Eric joins KORU Medical with more than 25 years of leadership experience across research & development, device engineering, drug–device combination product development, supply chain strategy, and end-to-end product lifecycle management. He most recently served as Global Head of Device Development Portfolio at Sanofi, where he built and led a global team, advanced connected and reusable delivery platforms, drove multiple regulatory and launch-readiness initiatives, and oversaw more than 80 pipeline assets across Specialty Care, General Medicine and Vaccines. Prior to Sanofi, Eric spent more than a decade at Bristol-Myers Squibb and Celgene in roles spanning device development, biologics commercialization, and global product strategy, where he supported launches for major immunology and hematology assets including therapies requiring complex injection and infusion delivery systems, and implemented programs that improved reliability, patient adherence, and supply continuity. His earlier engineering career at Becton Dickinson and Saint-Gobain included development of next-generation syringe platforms and quality, safety, and process-improvement initiatives. Mr. Schiller holds an MBA with a management concentration from Seton Hall University and a Bachelor of Science in Mechanical Engineering from the New Jersey Institute of Technology. He is an inventor on more than a dozen U.S. patents in injection devices, safety systems, and drug-delivery components.
Major Estimate Revision • Nov 19Consensus estimates of losses per share improve by 12%The consensus outlook for earnings per share (EPS) in fiscal year 2025 has improved. 2025 revenue forecast increased from US$39.9m to US$40.7m. EPS estimate increased from -US$0.08 per share to -US$0.07 per share. Medical Equipment industry in the US expected to see average net income growth of 15% next year. Consensus price target broadly unchanged at US$5.56. Share price rose 19% to US$4.45 over the past week.
お知らせ • Nov 18KORU Medical Systems to Present Promising Results on the Use of the FreedomEDGE Syringe Infusion System in Infusion Centers at ESID/EHA/SIOPE Focused Symposium 2025KORU Medical Systems, Inc. announced that the Company will present its latest research at the ESID/EHA/SIOPE Focused Symposium 2025 in Vienna, Austria, November 18-20. The poster presentation, titled "Comparing Mechanical Pump and Manual Push for Short- duration Subcutaneous Infusions: A Nursing Preference Survey Study," highlights results from a multicenter evaluation conducted by KORU Medical across nine hospitals in Denmark. The study compared KORU Medical's FreedomEDGE Infusion System with traditional healthcare provider manual push techniques for short-duration subcutaneous infusions in oncology and immunology settings, evaluating nurse satisfaction, patient experience, usability, and workflow efficiency. The study results demonstrated: High nurse satisfaction - 91% found the system easier to use, 91% reported faster setup time, 81% experienced reduced hand strain, and 97% reported increased time for patient interaction; High patient satisfaction with 73% observing improved comfort; 97% of respondents would recommend the FreedomEDGE Infusions. The growing adoption of subcutaneous oncology therapies presents both an opportunity and a challenge for infusion centers worldwide. With nurse resources under increasing strain, the FreedomEDGE infusion System offers a scalable, hands-free alternative that maintains safety and patient comfort while improving workflow efficiency. KORU Medical anticipates filing a 510(k) submission to the FDA for use with a commercialized oncology drug in either the fourth quarter of 2025 or in the first quarter of 2026. KORU Medical's Freedom Syringe Infusion System enables, simplifies, and enhances the delivery of large-volume subcutaneous drugs. Supporting drug products with various requirements for viscosity, flow rate, and delivered drug volume from 5mL-50mL+, the Freedom System is market proven with: 15+ years of patient self-administration in the home; 45,000+ patients and over 2M infusions annually; 97% adherence rate and 8 on-label subcutaneous drugs; Distributed across 30+ countries. The ESID-EHA-SIOPE Symposium 2025 brings together experts from the European Society for Immunodeficiencies (ESID), the European Hematology Association (EHA), and the European Society for Paediatric Oncology (SIOPE) to provide a comprehensive platform for exploring how immunodeficiencies can influence hematologic and oncologic conditions and vice versa, how each specialty offers unique insights that contribute to improving diagnosis, treatment, and management strategies.
Reported Earnings • Nov 14Third quarter 2025 earnings: EPS and revenues exceed analyst expectationsThird quarter 2025 results: US$0.017 loss per share (improved from US$0.034 loss in 3Q 2024). Revenue: US$10.4m (up 27% from 3Q 2024). Net loss: US$778.0k (loss narrowed 51% from 3Q 2024). Revenue exceeded analyst estimates by 7.6%. Earnings per share (EPS) also surpassed analyst estimates by 29%. Revenue is forecast to grow 16% p.a. on average during the next 3 years, compared to a 8.4% growth forecast for the Medical Equipment industry in the US. Over the last 3 years on average, earnings per share has increased by 16% per year and the company’s share price has also increased by 16% per year.
お知らせ • Nov 13KORU Medical Systems, Inc. Revises Earnings Guidance for the Year 2025KORU Medical Systems, Inc. revised earnings guidance for the year 2025. The company is raising full year 2025 net revenues guidance to $40.5 million - $41.0 million, representing year-over-year growth of 20% - 22%, from prior range of $39.5 million - $40.5 million.
お知らせ • Nov 05KORU Medical Systems, Inc. Announces Development Agreement for Innovation in Subcutaneous Immunoglobulin Infusion SystemsKORU Medical Systems, Inc. announced a development agreement with a global pharmaceutical company. The agreement allows for broad collaboration on next-generation infusion systems in subcutaneous immunoglobulin (SCIg) therapy for both commercial drugs and clinical programs. The agreement is for KORU Medical to support the qualification of an infusion system that can accommodate both vials and prefilled syringes (PFS). KORU Medical's Freedom60®? and FreedomEDGE®? infusion pumps were the first devices to be 510(k) cleared for use with prefilled syringes. The innovative system will be developed using KORU Medical's infusion technology along with SCHOTT TOPPAC®? polymer syringes. KORU Medical's FREEDOM Syringe Infusion System enables, simplifies, and enhances the delivery of large-volume subcutaneous drugs. Supporting drug products with various requirements for viscosity, flow rate, and delivered drug volume from 5mL-50mL+, the Freedom System is market proven with: 15+ years of patient self-administration in the home; 45,000+ patients and over 2M infusions annually; 97% adherence rate and 8 on-label subcutaneous drugs2; Distributed across 30+ countries.
Buy Or Sell Opportunity • Oct 28Now 20% undervaluedOver the last 90 days, the stock has risen 15% to US$4.01. The fair value is estimated to be US$5.01, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 10% over the last 3 years. Earnings per share has grown by 5.4%. Revenue is forecast to grow by 35% in 2 years. Earnings are forecast to grow by 99% in the next 2 years.
お知らせ • Oct 23KORU Medical Systems, Inc. to Report Q3, 2025 Results on Nov 12, 2025KORU Medical Systems, Inc. announced that they will report Q3, 2025 results on Nov 12, 2025
Buy Or Sell Opportunity • Oct 13Now 21% undervaluedOver the last 90 days, the stock has risen 38% to US$4.07. The fair value is estimated to be US$5.13, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 10% over the last 3 years. Earnings per share has grown by 5.4%. Revenue is forecast to grow by 35% in 2 years. Earnings are forecast to grow by 99% in the next 2 years.
Buy Or Sell Opportunity • Sep 22Now 21% undervaluedOver the last 90 days, the stock has risen 13% to US$4.02. The fair value is estimated to be US$5.11, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 10% over the last 3 years. Earnings per share has grown by 5.4%. Revenue is forecast to grow by 35% in 2 years. Earnings are forecast to grow by 99% in the next 2 years.
Buy Or Sell Opportunity • Sep 05Now 20% undervaluedOver the last 90 days, the stock has risen 32% to US$4.06. The fair value is estimated to be US$5.10, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 10% over the last 3 years. Earnings per share has grown by 5.4%. Revenue is forecast to grow by 35% in 2 years. Earnings are forecast to grow by 99% in the next 2 years.
分析記事 • Aug 14Investors Appear Satisfied With KORU Medical Systems, Inc.'s (NASDAQ:KRMD) Prospects As Shares Rocket 34%Despite an already strong run, KORU Medical Systems, Inc. ( NASDAQ:KRMD ) shares have been powering on, with a gain of...
Reported Earnings • Aug 08Second quarter 2025 earnings released: US$0.004 loss per share (vs US$0.022 loss in 2Q 2024)Second quarter 2025 results: US$0.004 loss per share (improved from US$0.022 loss in 2Q 2024). Revenue: US$10.2m (up 21% from 2Q 2024). Net loss: US$206.9k (loss narrowed 79% from 2Q 2024). Revenue is forecast to grow 15% p.a. on average during the next 3 years, compared to a 8.3% growth forecast for the Medical Equipment industry in the US. Over the last 3 years on average, earnings per share has increased by 5% per year but the company’s share price has increased by 17% per year, which means it is tracking significantly ahead of earnings growth.
New Risk • Aug 07New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of American stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (US$207k net loss in 2 years). Share price has been volatile over the past 3 months (11% average weekly change).
お知らせ • Aug 07KORU Medical Systems, Inc. Raises Earnings Guidance for the Year 2025KORU Medical Systems, Inc. raising earnings guidance for the year 2025. For the year, the company raising full year 2025 revenue guidance to $39.5 - $40.5 million, representing growth of 18% - 20%, from prior range of $38.5 - $39.5 million.
お知らせ • Jul 17KORU Medical Systems, Inc. to Report Q2, 2025 Results on Aug 06, 2025KORU Medical Systems, Inc. announced that they will report Q2, 2025 results on Aug 06, 2025
お知らせ • Jul 08KORU Medical Systems Appoints Adam Kalbermatten as Chief Commercial Officer, Effective July 28, 2025KORU Medical Systems, Inc. announced the appointment of Adam Kalbermatten as Chief Commercial Officer, effective July 28, 2025. Adam brings over two decades of commercial leadership experience in the medical device and pharmaceutical industries, with a proven track record of scaling businesses, building high-performing teams, and delivering customer-focused innovation. As Chief Commercial Officer, he will oversee all aspects of KORU Medical’s global commercial strategy—including marketing, sales, market access, and pharmaceutical customer engagement. Adam joins KORU Medical from Becton Dickinson (BD), where he most recently served as Vice President and General Manager, Advanced Drug Delivery Systems, leading growth initiatives across the injectable drug delivery platform. Prior to BD, Adam served as Chief Executive Officer of ZebraSci, a specialized provider of analytical and drug device combination product development services to pharmaceutical companies, where he led a successful turnaround and growth strategy resulting in an eventual acquisition of the company by BD. He also held global leadership roles at Terumo Medical Corporation, including Worldwide Director of Marketing and Worldwide Director of Business Development, where he helped shape the company’s global drug delivery strategy. Adam holds a Bachelor of Engineering in Mechanical Engineering and a Master of Engineering in Engineering Management from Stevens Institute of Technology, and an MBA with concentrations in Finance and Healthcare from Columbia Business School.
分析記事 • Jun 22Market Participants Recognise KORU Medical Systems, Inc.'s (NASDAQ:KRMD) Revenues Pushing Shares 27% HigherKORU Medical Systems, Inc. ( NASDAQ:KRMD ) shareholders would be excited to see that the share price has had a great...
Board Change • Jun 01Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 5 experienced directors. 1 highly experienced director. Director Ed Wholihan was the last director to join the board, commencing their role in 2023. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Reported Earnings • May 10First quarter 2025 earnings: EPS in line with analyst expectations despite revenue beatFirst quarter 2025 results: US$0.025 loss per share (improved from US$0.042 loss in 1Q 2024). Revenue: US$9.64m (up 18% from 1Q 2024). Net loss: US$1.17m (loss narrowed 40% from 1Q 2024). Revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 8.1% growth forecast for the Medical Equipment industry in the US. Over the last 3 years on average, earnings per share has fallen by 7% per year but the company’s share price has increased by 15% per year, which means it is well ahead of earnings.
New Risk • May 09New minor risk - ProfitabilityThe company is currently unprofitable and not forecast to become profitable over the next 2 years. Trailing 12-month net loss: US$6.1m Forecast net loss in 2 years: US$1.7m This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (US$1.7m net loss in 2 years). Share price has been volatile over the past 3 months (12% average weekly change).
お知らせ • May 08Koru Medical Systems, Inc. Raises Earnings Guidance for Full Year 2025KORU Medical Systems, Inc. raised earnings guidance for full year 2025. For the period the company raising revenue guidance to $38.5 million to $39.5 million from prior range of $38.0 million to $39.0 million.
分析記事 • May 08KORU Medical Systems, Inc. (NASDAQ:KRMD) Stocks Shoot Up 27% But Its P/S Still Looks ReasonableThose holding KORU Medical Systems, Inc. ( NASDAQ:KRMD ) shares would be relieved that the share price has rebounded...
お知らせ • Apr 23KORU Medical Systems, Inc., Annual General Meeting, May 14, 2025KORU Medical Systems, Inc., Annual General Meeting, May 14, 2025. Location: 100 corporate drive, mahwah, nj 07495, United States
お知らせ • Apr 17KORU Medical Systems, Inc. to Report Q1, 2025 Results on May 07, 2025KORU Medical Systems, Inc. announced that they will report Q1, 2025 results on May 07, 2025
お知らせ • Apr 09KORU Medical Systems, Inc. Announces Executive ChangesOn April 3, 2025, Kenneth Miller resigned his employment and position as Chief Commercial Officer of KORU Medical Systems, Inc. (the “Company”), effective immediately, to pursue a Chief Executive Officer role at an organization that does not compete with the Company. KORU Medical would like to thank Mr. Miller for his contributions to the Company and recognize the instrumental role he played in establishing and implementing strategic commercial growth priorities during his tenure. Rob Cannon will lead the Company’s commercial operations for the Core business until a succeeding Chief Commercial Officer is named. Mr. Cannon has served as the Company’s Vice President of Sales for North America since November 2021 and has over 30 years of experience in sales across the healthcare industry, including11 years with McKesson, a healthcare supply chain management company specializing in providing pharmaceuticals and healthcare services across the globe, where he led the strategy, planning and implementation of sales, and marketing strategies focused on specialty pharma and home infusion channels. The Company has retained the services of an executive search firm to commence the search for a new Chief Commercial Officer.
New Risk • Apr 08New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: US$98.3m This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. This is currently the only risk that has been identified for the company.
Recent Insider Transactions Derivative • Mar 20President notifies of intention to sell stockLinda Tharby intends to sell 30k shares in the next 90 days after lodging an Intent To Sell Form on the 19th of March. If the sale is conducted around the recent share price of US$2.83, it would amount to US$85k. For the year to December 2021, Linda's total compensation was 79% salary and 21% non-salary. Since March 2024, Linda has owned 1.82m shares directly. There have been no trades via on-market transactions or options from company insiders in the last 12 months.
Major Estimate Revision • Mar 19Consensus EPS estimates fall by 19%The consensus outlook for fiscal year 2025 has been updated. 2025 expected loss increased from -US$0.086 to -US$0.102 per share. Revenue forecast unchanged at US$38.4m. Medical Equipment industry in the US expected to see average net income growth of 18% next year. Consensus price target of US$5.70 unchanged from last update. Share price fell 11% to US$2.92 over the past week.
Reported Earnings • Mar 13Full year 2024 earnings: Revenues and EPS in line with analyst expectationsFull year 2024 results: US$0.13 loss per share (improved from US$0.30 loss in FY 2023). Revenue: US$33.6m (up 18% from FY 2023). Net loss: US$6.07m (loss narrowed 56% from FY 2023). Revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 7.7% growth forecast for the Medical Equipment industry in the US. Over the last 3 years on average, earnings per share has fallen by 19% per year but the company’s share price has only fallen by 3% per year, which means it has not declined as severely as earnings.
お知らせ • Mar 13KORU Medical Systems, Inc. Provides Earnings Guidance for the Full Year of 2025KORU Medical Systems, Inc. provided earnings guidance for the full year of 2025. For the full year of 2025, the company expects net revenues guidance of $38.0 - $39.0 million, representing growth of 13% - 16% over the prior year.
分析記事 • Mar 05KORU Medical Systems, Inc.'s (NASDAQ:KRMD) Stock Retreats 27% But Revenues Haven't Escaped The Attention Of InvestorsKORU Medical Systems, Inc. ( NASDAQ:KRMD ) shares have had a horrible month, losing 27% after a relatively good period...
お知らせ • Feb 20KORU Medical Systems, Inc. to Report Q4, 2024 Results on Mar 12, 2025KORU Medical Systems, Inc. announced that they will report Q4, 2024 results on Mar 12, 2025
お知らせ • Jan 31KORU Medical Systems Announces Phase III Clinical Trial Collaboration for a New Drug Indication in NephrologyKORU Medical Systems announced a collaboration with a global pharmaceutical manufacturer on a Phase III clinical trial for an expanded indication of a commercialized drug therapy. The expanded indication is intended to treat a rare renal disorder in a population of approximately 30,000 patients with a projected 300,000 annual infusions. This announcement highlights an additional collaboration between KORU Medical and its partners in the development of novel therapies and enhanced drug delivery experiences for patients living with rare conditions. The Phase III trial aims to assess the safety, efficacy, and performance of the drug to treat patients with complications from kidney transplants.
お知らせ • Jan 16KORU Medical Systems, Inc. Announces Preliminary Unaudited Revenues Guidance for the Fourth Quarter and Full Year Ended December 31, 2024KORU Medical Systems, Inc. announced preliminary unaudited revenues guidance for the fourth quarter and full year ended December 31, 2024. Preliminary, unaudited fourth quarter 2024 net revenues expected to be $8.9 million, representing growth of 23% over the prior year period. Preliminary, unaudited full year 2024 net revenues expected to be $33.7 million, representing growth of 18% over the prior year.
分析記事 • Nov 16KORU Medical Systems, Inc. (NASDAQ:KRMD) Released Earnings Last Week And Analysts Lifted Their Price Target To US$4.10As you might know, KORU Medical Systems, Inc. ( NASDAQ:KRMD ) just kicked off its latest quarterly results with some...
Reported Earnings • Nov 15Third quarter 2024 earnings: EPS and revenues exceed analyst expectationsThird quarter 2024 results: US$0.034 loss per share (further deteriorated from US$0.03 loss in 3Q 2023). Revenue: US$8.18m (up 17% from 3Q 2023). Net loss: US$1.58m (loss widened 16% from 3Q 2023). Revenue exceeded analyst estimates by 6.1%. Earnings per share (EPS) also surpassed analyst estimates by 10.0%. Revenue is forecast to grow 15% p.a. on average during the next 3 years, compared to a 8.2% growth forecast for the Medical Equipment industry in the US. Over the last 3 years on average, earnings per share has fallen by 32% per year but the company’s share price has only fallen by 2% per year, which means it has not declined as severely as earnings.
Price Target Changed • Nov 14Price target increased by 17% to US$4.10Up from US$3.50, the current price target is an average from 5 analysts. New target price is 33% above last closing price of US$3.08. Stock is up 40% over the past year. The company is forecast to post a net loss per share of US$0.13 next year compared to a net loss per share of US$0.30 last year.
お知らせ • Nov 14KORU Medical Systems, Inc. Raises Earnings Guidance for the Full Year 2024KORU Medical Systems, Inc. raised earnings guidance for the full year 2024. For the full year, the company expects net revenue to be in the range of $32.75 million to $33.25 million, representing growth of 15% to 17%; increased from previously issued guidance of $32.0 to $32.5 million, or 12% to 14%.
Seeking Alpha • Nov 06Impressive Turnaround At KORU MedicalSummary KORU Medical Systems is poised for growth with solid revenue increases, multiple growth drivers, and a chance to reach cash flow breakeven in Q4. The FREEDOM system, designed for at-home drug delivery, offers recurring revenue from consumables and is gaining market share in the SCIg market. International expansion and novel therapies present significant growth opportunities, with international revenue growing 46% and novel therapies progressing to Phase 3 trials. Financials are improving with a 22% revenue increase, 65% gross margin, and expected cash flow breakeven in Q4, making the shares a solid buy here. Read the full article on Seeking Alpha
お知らせ • Oct 24KORU Medical Systems, Inc. to Report Q3, 2024 Results on Nov 13, 2024KORU Medical Systems, Inc. announced that they will report Q3, 2024 results on Nov 13, 2024
分析記事 • Aug 29We're Interested To See How KORU Medical Systems (NASDAQ:KRMD) Uses Its Cash Hoard To GrowThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
Major Estimate Revision • Aug 14Consensus estimates of losses per share improve by 20%The consensus outlook for earnings per share (EPS) in fiscal year 2024 has improved. 2024 revenue forecast increased from US$31.8m to US$32.2m. EPS estimate increased from -US$0.166 per share to -US$0.133 per share. Medical Equipment industry in the US expected to see average net income growth of 17% next year. Consensus price target up from US$3.50 to US$3.60. Share price rose 8.5% to US$2.31 over the past week.
New Risk • Aug 08New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: US$97.5m This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (US$3.1m net loss in 2 years). Market cap is less than US$100m (US$97.5m market cap).
Reported Earnings • Aug 08Second quarter 2024 earnings: EPS and revenues exceed analyst expectationsSecond quarter 2024 results: US$0.022 loss per share (improved from US$0.055 loss in 2Q 2023). Revenue: US$8.43m (up 22% from 2Q 2023). Net loss: US$988.7k (loss narrowed 60% from 2Q 2023). Revenue exceeded analyst estimates by 11%. Earnings per share (EPS) also surpassed analyst estimates by 52%. Revenue is forecast to grow 15% p.a. on average during the next 3 years, compared to a 8.2% growth forecast for the Medical Equipment industry in the US. Over the last 3 years on average, earnings per share has fallen by 38% per year but the company’s share price has only fallen by 11% per year, which means it has not declined as severely as earnings.
お知らせ • Aug 08KORU Medical Systems, Inc. Revises Revenue Guidance for the Full Year 2024KORU Medical Systems, Inc. revised revenue guidance for the full year 2024. Raising full year 2024 net revenue guidance to $32.0 - $32.5, representing growth of 12-14%; increased from previously issued guidance of $31.2 - $32.2 million, or 10% to 13%. Raising full year 2024 gross margin guidance to 61% - 62%; increased from previously issued guidance of 59% - 61%.
分析記事 • Jul 30KORU Medical Systems, Inc. (NASDAQ:KRMD) Doing What It Can To Lift SharesWith a median price-to-sales (or "P/S") ratio of close to 3.2x in the Medical Equipment industry in the United States...
お知らせ • Jul 25KORU Medical Systems, Inc Announces Executive ChangesKORU Medical Systems, Inc. announced the promotion of Christopher Pazdan, to Chief Operating Officer, effective July 18, 2024. Mr. Pazdan has been with the organization since 2021, and last served as the Company’s Senior Vice President of Operations overseeing Quality, Regulatory, Operations, Supply Chain and Project Management. In his role as COO, Chris will also oversee the Research and Development organization and be responsible for the Company’s product development pipeline and innovation efforts. Chris joined KORU Medical Systems in 2021, as Vice President of Quality Assurance and Regulatory Affairs. In 2022, he was promoted to Senior Vice President of Operations, which included leading manufacturing, supply chain and the project management office. Chris brings more than 20 years of experience in the medical device industry including leadership roles at Hill-Rom and Becton Dickinson (formerly CareFusion/Cardinal Health) across a variety of strategic functions and roles. As part of this transition, Brian Case, Chief Technology Officer, will be leaving the Company on September 16, 2024.
お知らせ • Jul 18KORU Medical Systems, Inc. to Report Q2, 2024 Results on Aug 07, 2024KORU Medical Systems, Inc. announced that they will report Q2, 2024 results at 4:00 PM, US Eastern Standard Time on Aug 07, 2024
お知らせ • Jul 03+ 3 more updatesKORU Medical Systems, Inc.(NasdaqCM:KRMD) dropped from Russell Small Cap Comp Growth IndexKORU Medical Systems, Inc.(NasdaqCM:KRMD) dropped from Russell Small Cap Comp Growth Index
お知らせ • Jul 02KORU Medical Systems Receives Regulatory Clearance for FreedomEdge Infusion System in JapanKORU Medical Systems, Inc. announced that its FreedomEdge System has received regulatory clearance in Japan for the delivery of multiple drugs, including CSL Behring's Hizentra subcutaneous immunoglobulin (SCIg), Takeda Pharmaceutical's Cuvitru SCIg, and Sobi's Aspaveli paroxysmal nocturnal hemoglobinuria (PNH). The regulatory milestone marks a significant advancement in patient care in Japan, providing patients and healthcare providers with access to cutting-edge treatment options for Subcutaneous Immunoglobulin therapy (SCIg) and Paroxysmal Nocturnal Hemoglobinuria (PNH). the FreedomEdge System, known for its reliability, precision, and patient-friendly design, offers convenient and efficient administration of large volume subcutaneous therapies at home and in the clinic. The FreedomEdge System is designed to meet the diverse needs of patients and healthcare professionals, offering customizable features for personalized treatment experiences. Its compact and portable design allows for flexibility in treatment administration, enabling patients to manage their therapy effectively in various settings.
お知らせ • Jun 06KORU Medical Systems, Inc. Announces Collaboration with Global Pharmaceutical Company to Initiate Feasibility Study with Its Freedom Infusion System for FDA and EMA Approved Subcutaneous Oncology Biologic DrugKORU Medical Systems, Inc. announced a collaboration with a global pharmaceutical company to initiate a feasibility study with KORU Medical’s Freedom Infusion System for an FDA and EMA approved subcutaneous oncology biologic drug, that is currently being delivered via a manual syringe administration by a healthcare professional. The Freedom System is a purely mechanical ambulatory drug delivery device with 11 drugs approved on the label and over 40,000 patients globally. The system is designed to deliver large volumes of biologic medications from 2mL to over 100mL subcutaneously. The Freedom System is capable of allowing patients to self-administer their therapy at home and/or by healthcare professionals in a clinic setting.
Major Estimate Revision • May 08Consensus EPS estimates fall by 15%The consensus outlook for fiscal year 2024 has been updated. 2024 expected loss increased from -US$0.137 to -US$0.158 per share. Revenue forecast unchanged at US$31.8m. Medical Equipment industry in the US expected to see average net income growth of 18% next year. Consensus price target of US$3.50 unchanged from last update. Share price rose 4.1% to US$2.26 over the past week.
お知らせ • May 03KORU Medical Systems, Inc. reaffirms Financial Guidance for the Full Year of 2024·KORU Medical Systems, Inc. reaffirmed financial guidance for the full year of 2024. For the period, the company expects net revenue between $31.2 and $32.2 million, representing growth of 10% to 13% over the prior year.
Reported Earnings • May 02First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behindFirst quarter 2024 results: US$0.042 loss per share (improved from US$0.053 loss in 1Q 2023). Revenue: US$8.20m (up 11% from 1Q 2023). Net loss: US$1.94m (loss narrowed 20% from 1Q 2023). Revenue exceeded analyst estimates by 8.8%. Earnings per share (EPS) missed analyst estimates by 14%. Revenue is forecast to grow 15% p.a. on average during the next 3 years, compared to a 8.1% growth forecast for the Medical Equipment industry in the US. Over the last 3 years on average, earnings per share has fallen by 43% per year but the company’s share price has only fallen by 12% per year, which means it has not declined as severely as earnings.
お知らせ • Apr 19KORU Medical Systems, Inc. to Report Q1, 2024 Results on May 01, 2024KORU Medical Systems, Inc. announced that they will report Q1, 2024 results on May 01, 2024
お知らせ • Mar 29KORU Medical Systems, Inc., Annual General Meeting, May 09, 2024KORU Medical Systems, Inc., Annual General Meeting, May 09, 2024, at 08:00 Eastern Daylight. Location: 100 Corporate Drive, Mahwah New Jersey United States Agenda: To consider election of directors; to consider Advisory approval of the compensation of the Company’s executive officers; to consider ratification of the appointment of independent registered public accountants; to consider approval of the 2024 Omnibus Equity Incentive plan; and to consider transaction of any other business that may properly come before the meeting.
Reported Earnings • Mar 14Full year 2023 earnings: EPS misses analyst expectationsFull year 2023 results: US$0.30 loss per share (further deteriorated from US$0.19 loss in FY 2022). Revenue: US$28.5m (up 2.2% from FY 2022). Net loss: US$13.7m (loss widened 59% from FY 2022). Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 67%. Revenue is forecast to grow 16% p.a. on average during the next 3 years, compared to a 7.8% growth forecast for the Medical Equipment industry in the US. Over the last 3 years on average, earnings per share has fallen by 48% per year but the company’s share price has only fallen by 16% per year, which means it has not declined as severely as earnings.
お知らせ • Mar 14KORU Medical Systems, Inc. Provides Earnings Guidance for the Full Year 2024KORU Medical Systems, Inc. provided earnings guidance for the full year 2024. For the year, the company expected net revenue between $31.2 and $32.2 million, representing growth in the range of 10% to 13%.
お知らせ • Mar 12KORU Medical Systems, Inc. Announces A Feasibility Study to Enter Ambulatory Infusion Settings with A Commercialized BiologicKORU Medical Systems, Inc. announced a collaboration with a global pharmaceutical manufacturer to initiate a feasibility study with KORU's Freedom Infusion System for an already commercialized rare disease therapy. Upon successful completion of the feasibility study, KORU Medical intends to develop a customized Freedom System that will deliver this large volume therapy via subcutaneous administration. Healthcare providers administer this rare disease drug in the growing ambulatory infusion center (AIC) and ambulatory infusion suite (AIS) setting in the United States and the hospital setting in the European Union.
お知らせ • Feb 22KORU Medical Systems, Inc. to Report Q4, 2023 Results on Mar 13, 2024KORU Medical Systems, Inc. announced that they will report Q4, 2023 results on Mar 13, 2024
分析記事 • Feb 15Market Cool On KORU Medical Systems, Inc.'s (NASDAQ:KRMD) RevenuesThere wouldn't be many who think KORU Medical Systems, Inc.'s ( NASDAQ:KRMD ) price-to-sales (or "P/S") ratio of 3.6x...
Major Estimate Revision • Nov 15Consensus EPS estimates upgraded to US$0.18 loss, revenue downgradedThe consensus outlook for fiscal year 2023 has been updated. 2023 revenue forecast fell from US$31.0m to US$28.2m. 2023 losses expected to reduce from -US$0.206 to -US$0.178 per share. Medical Equipment industry in the US expected to see average net income growth of 25% next year. Consensus price target down from US$4.30 to US$3.80. Share price was steady at US$2.30 over the past week.
お知らせ • Nov 11Koru Medical Systems, Inc. Appoints Kenneth Miller as Chief Commercial OfficerKenneth Miller, age 55, has been appointed by KORU Medical Systems, Inc. (the “Company”) to serve in the newly created position of Chief Commercial Officer commencing November 6, 2023. Mr. Miller brings over 30 years of experience in leading teams in commercialization and marketing strategy and international expansion. Mr. Miller served as President and CEO of NASCO Healthcare Inc. from 2018 to January 2023. Prior to that, Mr. Miller served in various roles at Becton Dickinson from 2011 to 2018 with his last role as the Worldwide President Diabetes Care. He also held leadership roles in marketing, sales, and business development with Novo Nordisk Inc., Adams Respiratory Therapeutics, Inc., and Roche Laboratories. Mr. Miller earned his Bachelor of Arts in Business Management from State University of New York at Albany and his Master of Business Administration from The University of Chicago, Booth School of Business.
New Risk • Nov 10New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: US$99.9m This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (US$5.6m net loss in 2 years). Market cap is less than US$100m (US$99.9m market cap).
Reported Earnings • Nov 10Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behindThird quarter 2023 results: US$0.03 loss per share (further deteriorated from US$0.027 loss in 3Q 2022). Revenue: US$7.00m (down 9.8% from 3Q 2022). Net loss: US$1.37m (loss widened 12% from 3Q 2022). Revenue missed analyst estimates by 12%. Earnings per share (EPS) exceeded analyst estimates by 40%. Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 7.8% growth forecast for the Medical Equipment industry in the US. Over the last 3 years on average, earnings per share has fallen by 51% per year but the company’s share price has only fallen by 19% per year, which means it has not declined as severely as earnings.
お知らせ • Nov 08KORU Medical Systems, Inc. Receives FDA 510(k) Clearance for FREEDOM60 Infusion System With Hizentra 50 ML Prefilled SyringesKORU Medical Systems, Inc. announced that it received U.S. Food and Drug Administration (FDA) clearance for use of the FREEDOM60(R) Infusion System with Hizentra(R) 50 mL prefilled syringes (PFS). The FREEDOM(TM) Infusion System is the first and only infusion system cleared for use with prefilled syringes and, given the majority of patients are prescribed doses of 50 mL or greater, this clearance for FREEDOM60(R) significantly expands the benefits of PFS use, especially for those diagnosed with conditions requiring significantly higher doses of immunoglobulin. When using prefilled syringes with the FREEDOM(TM) Infusion System, KORU Medical has demonstrated that patients can experience up to an 80% reduction in drug preparation tasks when compared to using vials. The FDA approved the Hizentra(R) 50 mL prefilled syringe in April 2023, and CSL Behring has announced an early 2024 availability. Hizentra(R) is the most prescribed subcutaneous immunoglobulin and the first to be available in prefilled syringes.
お知らせ • Oct 26KORU Medical Systems, Inc. to Report Q3, 2023 Results on Nov 08, 2023KORU Medical Systems, Inc. announced that they will report Q3, 2023 results on Nov 08, 2023
Board Change • Oct 13High number of new directorsThere are 5 new directors who have joined the board in the last 3 years. Director Ed Wholihan was the last director to join the board, commencing their role in 2023. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.
分析記事 • Sep 21We're Hopeful That KORU Medical Systems (NASDAQ:KRMD) Will Use Its Cash WiselyThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
Reported Earnings • Aug 10Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behindSecond quarter 2023 results: US$0.055 loss per share (improved from US$0.065 loss in 2Q 2022). Revenue: US$6.94m (up 5.9% from 2Q 2022). Net loss: US$2.50m (loss narrowed 15% from 2Q 2022). Revenue missed analyst estimates by 4.0%. Earnings per share (EPS) exceeded analyst estimates by 12%. Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 7.8% growth forecast for the Medical Equipment industry in the US. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 27 percentage points per year, which is a significant difference in performance.
お知らせ • Aug 10KORU Medical Systems, Inc. Updates Revenue Guidance for the Full Year 2023KORU Medical Systems, Inc. updated revenue guidance for the full year 2023. For the year, the company reducing net revenue guidance to $31.0 million - $32.5 million, representing growth in the range of 11%-17% from prior guidance of $32.5 million - $33.5 million, representing growth in the range of 17-20%.
Price Target Changed • Aug 03Price target decreased by 10% to US$4.33Down from US$4.83, the current price target is an average from 3 analysts. New target price is 70% above last closing price of US$2.55. Stock is down 5.6% over the past year. The company is forecast to post a net loss per share of US$0.20 next year compared to a net loss per share of US$0.19 last year.
お知らせ • Aug 03+ 1 more updateKORU Medical Systems, Inc. Provides Revenue Guidance for the Full Year 2023KORU Medical Systems, Inc. provided revenue guidance for the full year 2023. For the year, the company net revenues are now expected to be between $31 million and $32.5 million, representing revenue growth in the range of 11%-17% from the prior year.
お知らせ • Aug 01KORU Medical Systems, Inc. to Report Q2, 2023 Results on Aug 09, 2023KORU Medical Systems, Inc. announced that they will report Q2, 2023 results on Aug 09, 2023
分析記事 • Jul 14Market Cool On KORU Medical Systems, Inc.'s (NASDAQ:KRMD) Earnings Pushing Shares 28% LowerKORU Medical Systems, Inc. ( NASDAQ:KRMD ) shareholders that were waiting for something to happen have been dealt a...
お知らせ • Jul 11KORU Medical Systems, Inc. Announces 510(K) Submission for Freedom60®? Infusion System with Hizentra®? 50 Ml Preilled SyringesKORU Medical Systems, Inc. announced that it has submitted a 510(k) premarket notification submission to the U.S. Food and Drug Administration for the use of its FREEDOM60®? Infusion System with Hizentra®? 50 mL prefilled syringes. The FDA approved the 50 mL Hizentra prefilled syringe in April 2023. Hizentra is the most prescribed subcutaneous immunoglobulin and the first to be available in prefilled syringes.
